Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | METAP2 | P50579 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | CRHBP | P24387 | 1/20 | 0.34 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18329485 | 0.83 | MEN1 (0.45) | MEN1KMT2ASMN1; SMN2MAPK1HTT | |
| SCHEMBL421498 | 0.82 | HTT (0.35) | MEN1KMT2ANTRK1HTTKDM4C | |
| SCHEMBL22894087 | 0.82 | HTT (0.35) | MEN1KMT2ANTRK1HTTKDM4C | |
| SCHEMBL9955375 | 0.79 | CA12 (0.41) | KMT2AMAPK1HTTKDM4CNOTUM | |
| SCHEMBL10598245 | 0.79 | METAP2 (0.41) | MEN1KMT2ASMN1; SMN2MAPK1METAP2 | |
| SCHEMBL6418751 | 0.79 | CES2 (0.40) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1018937 | 0.79 | MEN1 (0.42) | MEN1KMT2ASMN1; SMN2MAPK1HTT | |
| SCHEMBL8218259 | 0.78 | METAP2 (0.41) | MEN1KMT2ASMN1; SMN2METAP2 | |
| SCHEMBL22980390 | 0.78 | DPP4 (0.47) | NOTUMHPGD | |
| SCHEMBL9381963 | 0.78 | CA12 (0.46) | MEN1KMT2ASMN1; SMN2MAPK1METAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11040966-B2 | Benzimidazole-proline derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-06-22 | — | — | US | disclosed |
| US-20190263797-A1 | BENZIMIDAZOLE-PROLINE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-08-29 | — | — | US | disclosed |
| EP-2906553-B1 | OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI (HETERO )ARYL]-[2-(META BI (HETERO)ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-06-26 | — | — | EP | disclosed |
| US-10329287-B2 | Benzimidazole-proline derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-06-25 | — | — | US | disclosed |
| US-9896452-B2 | Substituted prolines/piperidines as orexin receptor antagonists | EOLAS THERAPEUTICS, INC. (US) | 2018-02-20 | — | — | US | disclosed |
| US-20170305897-A1 | BENZIMIDAZOLE-PROLINE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-10-26 | — | — | US | disclosed |
| US-9732075-B2 | Benzimidazole-proline derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-08-15 | — | — | US | disclosed |
| US-20170101410-A1 | SUBSTITUTED PROLINES / PIPERIDINES AS OREXIN RECEPTOR ANTAGONISTS | EOLAS THERAPEUTICS, INC. | 2017-04-13 | — | — | US | disclosed |
| EP-2855453-B1 | BENZIMIDAZOLE-PROLINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2016-12-07 | — | — | EP | disclosed |
| US-9499517-B2 | Substituted prolines / piperidines as orexin receptor antagonists | EOLAS THERAPEUTICS, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| EP-2246333-A1 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | Abbott Laboratories (US) | 2010-11-03 | — | — | EP | disclosed |
| EP-1638941-B1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABBOTT LAB (US) | 2010-06-02 | — | — | EP | disclosed |
| US-20090286784-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2009-11-19 | — | — | US | disclosed |
| US-7598283-B2 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | ABBOTT LABORATORIES, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20080076767-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABBVIE INC. | 2008-03-27 | — | — | US | disclosed |
| US-7297709-B2 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | ABBOTT LABORATORIES (US) | 2007-11-20 | — | — | US | disclosed |
| EP-1638941-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2006-03-29 | — | — | EP | disclosed |
| US-20050020603-A1 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | ABBVIE INC. | 2005-01-27 | — | — | US | disclosed |
| WO-2004113304-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2004-12-29 | — | — | WO | disclosed |
| US-20040235892-A1 | Indazole and benzisoxazole kinase inhibitors | ABBOTT LABORATORIES | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076767-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABL1, BLK, BTK | MEN1 2549/4885KMT2A 1422/4885SMN1; SMN2 4807/4885 |
| US-20170101410-A1 | SUBSTITUTED PROLINES / PIPERIDINES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, OPRL1 | MEN1 885/4885KMT2A 809/4885SMN1; SMN2 856/4885 |
| US-20050020603-A1 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | ABL1, BLK, BTK | MEN1 2549/4885KMT2A 1422/4885SMN1; SMN2 4807/4885 |
| US-10329287-B2 | Benzimidazole-proline derivatives | HCRTR1, HCRTR2, NPY1R | MEN1 1769/4885KMT2A 1281/4885SMN1; SMN2 2907/4885 |
| US-11040966-B2 | Benzimidazole-proline derivatives | HCRTR1, HCRTR2, NPY1R | MEN1 1769/4885KMT2A 1281/4885SMN1; SMN2 2907/4885 |
| US-20040235892-A1 | Indazole and benzisoxazole kinase inhibitors | ABL1, MAP3K19, MAP3K1 | MEN1 2321/4885KMT2A 1561/4885SMN1; SMN2 4755/4885 |
| US-20090286784-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABL1, BLK, BTK | MEN1 2549/4885KMT2A 1422/4885SMN1; SMN2 4807/4885 |
| US-20190263797-A1 | BENZIMIDAZOLE-PROLINE DERIVATIVES | HCRTR1, HCRTR2, NPY1R | MEN1 1769/4885KMT2A 1281/4885SMN1; SMN2 2907/4885 |
| US-20170305897-A1 | BENZIMIDAZOLE-PROLINE DERIVATIVES | HCRTR1, HCRTR2, NPY1R | MEN1 1769/4885KMT2A 1281/4885SMN1; SMN2 2907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.